Resources

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).